Does Steroid Plus CO2 Laser Improve Lichen Sclerosus Symptoms Compared to Steroids Alone?
- Conditions
- Vulvar Lichen Sclerosus
- Interventions
- Device: MonaLisa TouchDrug: Topical steroid
- Registration Number
- NCT05243563
- Lead Sponsor
- University of South Alabama
- Brief Summary
This study will compare the effects of fractionated CO2 laser plus topical steroids versus topical steroids alone in treatment of lichen sclerosus.
- Detailed Description
Vulvar lichen sclerosus is a common benign skin condition which causes pain and itching. Topical steroids have been the main treatment. A recent study showed that fractionated CO2 laser treatment is non inferior and actually may improve subjective symptoms compared to topical steroids with no serious safety or adverse events. Because steroids reduce risk of vulvar cancer in patients with lichen sclerosus, the investigators hypothesize that steroids in addition to the fractionated laser will provide greater symptom relief while still allowing patient the benefits of steroid treatment.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 52
- women with biopsy proven lichen sclerosus and significant symptoms based on Skindex-29 scores >21
- prior vaginal mesh or pelvic radiation
- active genital infection
- Current or past gynecologic malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Fractionated CO2 laser plus topical steroids MonaLisa Touch 3 laser treatments at 6 week intervals for 6 months by a single trained operator Fractionated CO2 laser plus topical steroids Topical steroid 3 laser treatments at 6 week intervals for 6 months by a single trained operator topical steroids alone Topical steroid self-applied topical steroid therapy using clobetasol propionate 0.05%
- Primary Outcome Measures
Name Time Method Change in Skindex-29 score Completed by the subject at baseline and 6 months. The Skindex-29 is a validated tool to assess impact of a chronic skin condition on a person's quality of life. It has been previously used to describe the effects of a treatment and to compare treatments. Values range from 1 (Never) to 5 (All the time). The higher the score, the worse the outcome.
- Secondary Outcome Measures
Name Time Method Change in Objective Visual Analog Scale Scored by the provider at baseline and 6 months Providers will use this scale to objectively assess vulvar appearance. The tool uses is scored from 0 to 3 (0= absent, 1= mild, 2= moderate, 3= severe) on nine different features of lichen sclerosus (white plaques or hypopigementation, cigarette paper or thin skin, introital narrowing, perianal involvment, loss of labia minora, fusion of labia minora, vulvar fissures, and vulvar erosion). A higher score indicates a higher severity. A higher change in score indicates greater improvement.
Global Subjective Visual Analog Scale Scored by the provider at 6 months Providers will use this scale to subjectively assess improvement in vulvar appearance. The provider will grade the improvement from baseline on a 6 point scale, with 0 being "much worse" and 5 being "much better".
Change in Vulvovaginal Symptoms Questionnaire (VSQ) score (Total Score) Administered at baseline and at 6 months by the provider. This 21 item questionnaire assess four aspects impacting quality of life for patients with vulvovaginal skin diseases: symptoms, emotions, life impact and sexual impact. A higher score corresponds to more bothersome symptoms. The values are 0 (No) or 1 (Yes). The higher the score, the worse the outcome. A higher change in these scores indicates more improvement.
Patient reported satisfaction with treatment Administered by an investigator to the subject at 6 months. 5 point scale of satisfaction: 0 = very unsatisfied, 1 = unsatisfied, 2 = neutral, 3 = satisfied, 4 = very satisfied
Change in Vulvovaginal Symptoms Questionnaire score (Symptoms Component only) Administered at baseline and at 6 months by the provider. A subset of the total score on the VSQ, looking at symptoms only. A higher score corresponds to more bothersome symptoms. The values are 0 (No) or 1 (Yes). The higher the score, the worse the outcome. A higher change in these scores indicates more improvement.
Change in Vulvovaginal Symptoms Questionnaire score (Emotion Component only) Administered at baseline and at 6 months by the provider. A subset of the total score on the VSQ, looking at scores for emotions questions only. A higher score corresponds to more emotional impact. The values are 0 (No) or 1 (Yes). The higher the score, the worse the outcome. A higher change in these scores indicates more improvement.
Change in Vulvovaginal Symptoms Questionnaire score (Life Impact Component only) Administered at baseline and at 6 months by the provider. A subset of the total score on the VSQ, looking at scores for life impact questions only. A higher score corresponds to more impact. The values are 0 (No) or 1 (Yes). The higher the score, the worse the outcome. A higher change in these scores indicates more improvement.
Change in Vulvovaginal Symptoms Questionnaire score (Sexual Impact Component only) Administered at baseline and 6 months by an investigator to the subject A subset of the total score on the VSQ, looking at scores for sexual impact questions only. A higher score corresponds to more impact. The values are 0 (No) or 1 (Yes). The higher the score, the worse the outcome. A higher change in these scores indicates more improvement.
Change in symptom subjective visual analog score Administered at baseline and 6 months by an investigator to the subject This measures the subjects perception of 9 key vulvovaginal symptoms: itching, burning, irritation, pain with intercourse, tearing of vulvar skin, painful urination and painful defecation. Each is scored from 0 -10, with 10 indicating the most symptoms.
Trial Locations
- Locations (2)
USA Health Children's and Women's Hospital
🇺🇸Mobile, Alabama, United States
USA Health Strata Patient Center
🇺🇸Mobile, Alabama, United States